TransMedics Group (TMDX) last issued guidance on February 24, 2026 for fiscal year 2026. The company guided revenue in the range of $727.00M - $757.00M for the period.
Compared to prior guidance, TransMedics Group raised its revenue forecast from a prior range of $595.00M - $605.00M.
TransMedics Group has issued 17 guidance updates between May 3, 2022 and February 24, 2026. During this period, the company raised its outlook 13 times and lowered it 1 time, providing investors with insight into management's evolving expectations.
Review all historical guidance issued by TransMedics Group, including EPS and revenue forecasts across quarterly and annual periods.
The most recent guidance for TransMedics Group (TMDX) was reported on February 24, 2026 for the fiscal year 2026. TransMedics Group forecasted revenue between $727.00M and $757.00M for the period.
TransMedics Group (TMDX) guided revenue in the range of $727.00M to $757.00M for the fiscal year 2026.
TransMedics Group (TMDX) raised its revenue guidance from a prior range of $595.00M - $605.00M to $727.00M - $757.00M for the fiscal year 2026.
TransMedics Group (TMDX) last issued guidance on February 24, 2026 for the fiscal year 2026.